← All trials
NCT05182125
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 25, 2021
- Primary completion
- Sep 14, 2023
- Completion date
- Nov 6, 2025
- First posted
- Jan 10, 2022
- Last posted
- Aug 2, 2022
- Enrollment
- 34
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HIV Vaccine Trials NetworkLead sponsor
- Department of Health and Human ServicesCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.